anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 102
Group description: After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.

EXPAREL: transversus abdominis plane injection
Eligibility criteria:
Inclusion Criteria:

• All patients undergoing elective laparoscopic or open colorectal resections who are eligible for IT

Age >18 years
BMI <40
Ability to understand and read English

Exclusion Criteria:

• Not able or unwilling to sign consent.

Currently pregnant or lactating.
Patients with chronic pain, requiring daily opiate use at time of surgery.
Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
Patients requiring emergent surgery.
Abdominoperineal resections
Any contraindications to neuraxial analgesia (coagulopathy, localized infection at the potential site of injection, pre-existing spinal canal pathology)
Patients with a diagnosis of inflammatory bowel disease
Intervention: Hydromorphone
Trial phase: Not Applicable
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 98
Group description: single injection intrathecal hydromorphone analgesia given preoperatively

Intrathecal hydromorphone: Intrathecal opioid administration
Eligibility criteria:
Inclusion Criteria:

• All patients undergoing elective laparoscopic or open colorectal resections who are eligible for IT

Age >18 years
BMI <40
Ability to understand and read English

Exclusion Criteria:

• Not able or unwilling to sign consent.

Currently pregnant or lactating.
Patients with chronic pain, requiring daily opiate use at time of surgery.
Patients intolerant of opiates, NSAIDS, acetaminophen or local anesthetics.
Patients requiring emergent surgery.
Abdominoperineal resections
Any contraindications to neuraxial analgesia (coagulopathy, localized infection at the potential site of injection, pre-existing spinal canal pathology)
Patients with a diagnosis of inflammatory bowel disease
Intervention: Nitric Oxide
Trial phase: Phase 3
ATC code: R07AX01
SMILES: [N]=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 107
Group description: A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.

Sufentanil Tablet 30 mcg
Eligibility criteria:
Inclusion Criteria (additional criteria not specified here):

Patients who are scheduled to undergo one of the following procedures with general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation:

abdominoplasty
open tension-free inguinal hernioplasty (Lichenstein repair with mesh)
laparoscopic abdominal surgery
Patients classified as American Society of Anesthesiologists (ASA) class I - III (Appendix I).
Female patients of childbearing potential must be using an effective method of birth control at the time of screening visit
Patients who are expected to have moderate-to-severe post-operative pain for at least 24 hours.

Exclusion Criteria (additional criteria not specified here):

Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery
Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug.
Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP).
Patients who previously have had abdominoplasty or have had an inguinal hernia repair on the same side.
Intervention: Midazolam
Trial phase: Phase 4
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 42
Group description: Patients will receive 0.2 mg/kg of intranasal midazolam

Midazolam: midazolam 0.2 mg/kg given intranasally
Eligibility criteria:
Inclusion Criteria:

Children aged 18 months-7 years, scheduled for a minor Ear/Nose/Throat surgical procedure requiring mask anesthesia
American Society of Anesthesiologists (ASA) Class 1 or 2
Parent willing and able to provide written informed consent
Parent willing and able to complete the Observed Behavioral Distress (OBD) Visual Assessment Scale (VAS)

Exclusion Criteria:

ASA Class 3 or greater
History of allergy to midazolam or xylocaine
Presence of acute respiratory infection at time of surgery
Parent unwilling or unable to provide informed consent
Parent unwilling or unable to complete the OBD VAS
Intervention: Medroxyprogesterone acetate
Trial phase: Phase 4
ATC code: G03AA08 | G03AA17 | G03AC06 | G03DA02 | G03FA12 | G03FB06 | L02AB02
SMILES: [H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 19
Group description: Participants receiving DMPA administered every 12 weeks at the standard dose of 150 mg intramuscular injection, beginning from Week 3 of study enrollment and repeated at Week 15
Eligibility criteria:
Inclusion Criteria:

Female
Age 18-45 years
Normal menses (22-35 day intervals) for at least 3 cycles
Intact uterus and cervix
Interested in to DMPA, Eng-Implant or Lng-IUD or ParaGuard
Willing to delay initiation of hormonal contraception for up to 1 month
Willing to use condoms or abstain from sexual intercourse for at least 48 hours before each genital tract sampling (condoms will be made available)
Able and willing to provide informed consent, and undergo serial blood and cervicovaginal lavage (CVL) sampling
Negative HIV screening

Exclusion Criteria:

Pregnant within the last 3 months
Breastfeeding
History of loop electrosurgical excision procedure, conization, or cryosurgery within the past year
Use of hormonal contraception or IUD in the past 6 months
Known history of medical condition that would interfere with the conduct of the study
Symptomatic vaginal infection or genital ulcer disease at screening
Taking medications that interact with selected contraceptive
Contraindications to selected contraceptive per the Centers for Disease Control and Prevention (CDC) medical eligibility criteria or judgment of clinician
Intervention: Kenalog
Trial phase: Phase 3
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 161
Group description: FX006: Single 5 mL IA injection
Eligibility criteria:
Inclusion Criteria:

Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions
Male or female >=40 years of age
Has symptoms associated with OA of the index knee for at least 6 months prior to Screening
Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA
Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee per Screening X-ray
Index knee pain for > 15 days over the last month
Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)
Body mass index (BMI) ≤ 40 kg/m2
Willingness to abstain from use of restricted medications

Exclusion Criteria:

Any condition that could possibly confound the patient's assessment of index knee pain in judgement of the investigator (i.e., iIpsilateral hip OA, gout, radicular low back pain and hip pain that is referred to the knee that could cause misclassification, pain in any other area of the lower extremities or back that is equal or greater than the index knee pain)
Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease
History of infection in the index knee
Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening
Unstable joint within 12 months of screening
IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening
IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening
Intramuscular (IM) or oral corticosteroids (investigational or marketed) within 1 month of Screening
Any other IA investigational drug/biologic within 6 months of Screening
Prior use of FX006
Women of child-bearing potential not using effective contraception or who are pregnant or nursing
Intervention: Kenalog
Trial phase: Phase 3
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 161
Group description: TCA IR: Single 1 mL IA injection
Eligibility criteria:
Inclusion Criteria:

Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions
Male or female >=40 years of age
Has symptoms associated with OA of the index knee for at least 6 months prior to Screening
Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA
Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee per Screening X-ray
Index knee pain for > 15 days over the last month
Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)
Body mass index (BMI) ≤ 40 kg/m2
Willingness to abstain from use of restricted medications

Exclusion Criteria:

Any condition that could possibly confound the patient's assessment of index knee pain in judgement of the investigator (i.e., iIpsilateral hip OA, gout, radicular low back pain and hip pain that is referred to the knee that could cause misclassification, pain in any other area of the lower extremities or back that is equal or greater than the index knee pain)
Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease
History of infection in the index knee
Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening
Unstable joint within 12 months of screening
IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening
IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening
Intramuscular (IM) or oral corticosteroids (investigational or marketed) within 1 month of Screening
Any other IA investigational drug/biologic within 6 months of Screening
Prior use of FX006
Women of child-bearing potential not using effective contraception or who are pregnant or nursing
Intervention: Aripiprazole
Trial phase: Phase 4
ATC code: N05AX12
SMILES: O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Intervention arm
Eligibility criteria:
Inclusion Criteria:

consent obtained from patients and their parents (assent for patients under 18);
age 12-25 years (inclusive);
English-speaking;
at least one positive (Scale A) SOPS score of 3-5, i.e., moderate, moderately severe or severe.

Exclusion Criteria:

lifetime diagnosis of an Axis I psychotic disorder, including: schizophreniform disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or major depression with psychotic features;
current psychosis (any positive symptom SOPS score of 6, i.e., extreme);
current diagnosis of Major Depressive Disorder, single episode or recurrent, severe without psychotic features;
current stimulant treatment;
history of neurological, neuroendocrine or other medical condition known to affect the brain;
any significant medical condition that contra-indicates treatment with either aripiprazole or fluoxetine;
past or current substance dependence; sunstance abuse within the last 4 weeks;
IQ < 70.
Intervention: Methenamine Hippurate
Trial phase: Not Applicable
SMILES: C1N2CN3CN1CN(C2)C3.O=C(O)CNC(=O)c1ccccc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 103
Group description: Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.

methenamine hippurate: A urinary antiseptic used for prevention of UTI
Eligibility criteria:
Inclusion Criteria:

female;
patients who are able to read and write English;
18 years of age or older;
underwent surgery for pelvic organ prolapse, urinary incontinence, or both;
require post-operative short-term transurethral catheterization for greater than 24 hours.

Exclusion Criteria:

patients undergoing surgical intervention for sacral neuromodulation, or mesh excision;
patients requiring long-term catheterization secondary to injury to the urinary tract;
patients who pass their post-operative trial void and thus, do not require additional catheterization;
patients requiring catheterization for less than 24 hours;
pregnant patients;
patients who are breast-feeding;
allergy to methenamine hippurate or fluroquinolones (either ciprofloxacin or levofloxacin);
impaired renal or hepatic function;
pre-operative urinary retention;
patients who are currently using sulfonamides;
patients who have severe dehydration;
patients using tizanidine;
patients sensitive to quinolones class;
patients using theophylline; patients with myasthenia gravis;
patients with prolongation of QT interval.
Intervention: Ciprofloxacin
Trial phase: Not Applicable
ATC code: J01MA02 | J01RA10 | J01RA11 | J01RA12 | S01AE03 | S02AA15 | S03AA07
SMILES: O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 94
Group description: Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.

Ciprofloxacin: An antibiotic used for treatment and prevention of UTI
Eligibility criteria:
Inclusion Criteria:

female;
patients who are able to read and write English;
18 years of age or older;
underwent surgery for pelvic organ prolapse, urinary incontinence, or both;
require post-operative short-term transurethral catheterization for greater than 24 hours.

Exclusion Criteria:

patients undergoing surgical intervention for sacral neuromodulation, or mesh excision;
patients requiring long-term catheterization secondary to injury to the urinary tract;
patients who pass their post-operative trial void and thus, do not require additional catheterization;
patients requiring catheterization for less than 24 hours;
pregnant patients;
patients who are breast-feeding;
allergy to methenamine hippurate or fluroquinolones (either ciprofloxacin or levofloxacin);
impaired renal or hepatic function;
pre-operative urinary retention;
patients who are currently using sulfonamides;
patients who have severe dehydration;
patients using tizanidine;
patients sensitive to quinolones class;
patients using theophylline; patients with myasthenia gravis;
patients with prolongation of QT interval.
Intervention: Gabapentin
Trial phase: Phase 4
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 112
Group description: Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
Eligibility criteria:
Inclusion Criteria:

The patient must be female and planning to have a laparoscopic or robotic assisted procedure for benign gynecologic indications.
Patients must be treated in the department of Obstetrics and Gynecology in the division of Minimally Invasive Gynecologic Surgery.
The patient must be in the age range of 18-80 years, in general good health and able to comply with study procedures.

Exclusion Criteria:

Male patients will be excluded from this study.
Patients under 18 years old will be excluded from this study.
Pregnant patients. All patients will have a routine pre-operative urine HCG to exclude pregnancy.
Patients having abdominal, vaginal or hysteroscopic procedures
Allergy to gabapentin
Chronic use of gabapentin (greater than 6 months)
Intervention: Metronidazole
Trial phase: Not Applicable
ATC code: A01AB17 | A02BD01 | A02BD02 | A02BD03 | A02BD08 | A02BD11 | A02BD13 | A02BD15 | D06BX01 | G01AF01 | G01AF20 | J01RA03 | J01RA04 | J01RA10 | J01RA14 | J01XD01 | P01AB01 | P01AB51 | P01AB52
SMILES: Cc1ncc([N+](=O)[O-])n1CCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 220
Group description: pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily

Reverse hybrid therapy: pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
Eligibility criteria:
Inclusion Criteria:

Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis

Exclusion Criteria:

previous H pylori-eradication therapy
ingestion of antibiotics or bismuth within the prior 4 weeks
patients with allergic history to the medications used
patients with previous gastric surgery
the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
pregnant women
Intervention: Rasagiline
Trial phase: Phase 2
ATC code: N04BD02
SMILES: C#CCN[C@@H]1CCc2ccccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.

Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).

Rasagiline
Eligibility criteria:
Inclusion Criteria:

Males or females 50 to 90 of age inclusive.
Diagnosis of probable AD (NINCDS-ADRDA criteria)
Positive fluoro-deoxyglucose PET ([18F]-FDG PET) scan compatible with AD as determined by the ADM Diagnostics LLC (ADMdx) Criteria at screening
Mini Mental Status Exam = 12 - 22 (inclusive)
Must have a study partner who is able and willing to comply with all required study procedures.
Have at least eight years of education and should have previously (in pre-AD condition) been capable of reading, writing, and communicating effectively with others in English.
If receiving therapy with a cholinesterase inhibitor and/or memantine, the dose of these agents has been stable for at least 3 months prior to screening

Exclusion Criteria:

Any non-AD neurological disease
MRI findings indication of a non-AD diagnosis
Screening laboratory studies that are 1.5 times above or below the highest and lowest range of normal for each test respectively
History of melanoma; history of malignancy within the past five years with the exception of basal cell or squamous cell cancer, in-situ cervical cancer, or localized prostate cancer
Intervention: SILVER DIAMMINE FLUORIDE
Trial phase: Phase 2 | Phase 3
SMILES: N.N.[Ag+].[F-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 323
Group description: the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.

silver diammine fluoride: topical application of the SDF solution onto tooth root surfaces
Eligibility criteria:
Inclusion criteria:

have at least 5 teeth with exposed root surfaces and not indicated for extraction, and
living in the community and have self-care ability for normal daily activities.

Exclusion Criteria:

have life-threatening or serious health problems,
have cognitive problems in communication or in receiving oral hygiene instructions
have salivary gland diseases or received radiotherapy in the head and neck region.